← Back to Clinical Trials
Recruiting NCT06072911

NCT06072911 Continence, Sexual Function, Fitness and the Health of Men After Surgery for Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06072911
Status Recruiting
Phase
Sponsor University of Alberta
Condition Prostate Cancer
Study Type INTERVENTIONAL
Enrollment 106 participants
Start Date 2024-02-27
Primary Completion 2026-06-30

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Pelvic floor exercise programGeneral exercisePhysical Activity Counseling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 106 participants in total. It began in 2024-02-27 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate cancer. As part of this study, all participants will receive resources offered by Alberta Health Services regarding pre- and post-prostatectomy care, including information on pelvic floor exercises. Through the CONTROL 4 LIFE study, the investigators will also be evaluating outcomes related to physical activity, fitness and quality of life. These assessments will enable the investigators to better understand how well and how long it takes for individuals to recover after surgery for prostate cancer.

Eligibility Criteria

Inclusion Criteria: * have a diagnosis of prostate cancer (stage I to IV); * be scheduled for a prostatectomy surgery (any surgical approach); * have no restriction to participate in at least mild levels of physical activity, as confirmed by the Physical Activity Readiness Questionnaire (PAR-Q+); * speak and understand English. * adult: 18 years of age or older * optional exercise component: willing and able to commit to the 12-week intervention Exclusion Criteria: * have any medical conditions that may interfere with continence (i.e. neurological diseases); * have any contraindications to exercise testing or training; * have recent (\>6 months) modifications to any medication aiming to reduce urinary incontinence (i.e. Myrbetric); * do not have regular access to the internet and a smart device or a computer at home/ at their community center; * are already receiving a pelvic floor exercise program through a pelvic floor physical therapist from their community.

Contact & Investigator

Central Contact

Margaret L McNeely

✉ mmcneely@ualberta.ca

📞 780-492-6007

Principal Investigator

Nathan Hoy, MD

PRINCIPAL INVESTIGATOR

University of Alberta

Frequently Asked Questions

Who can join the NCT06072911 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06072911 currently recruiting?

Yes, NCT06072911 is actively recruiting participants. Contact the research team at mmcneely@ualberta.ca for enrollment information.

Where is the NCT06072911 trial being conducted?

This trial is being conducted at Edmonton, Canada.

Who is sponsoring the NCT06072911 clinical trial?

NCT06072911 is sponsored by University of Alberta. The principal investigator is Nathan Hoy, MD at University of Alberta. The trial plans to enroll 106 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology